TY  - CHAP
M1  - Book, Section
TI  - Chapter 54. Cancer Chemotherapy
A1  - Trevor, Anthony J.
A1  - Katzung, Bertram G.
A1  - Kruidering-Hall, Marieke M.
A1  - Masters, Susan B.
PY  - 2013
T2  - Katzung & Trevor's Pharmacology: Examination & Board Review, 10e
AB  - Cancer  chemotherapy  remains  an  intriguing  area  of  pharmacology.  On  the  one  hand,  use  of  anticancer  drugs  produces  high  rates  of  cure  of  diseases,  which,  without  chemotherapy,  result  in  extremely  high  mortality  rates  (eg,  acute  lymphocytic  leukemia  in  children,  testicular  cancer,  and  Hodgkin's  lymphoma).  On  the  other  hand,  some  types  of  cancer  are  barely  affected  by  currently  available  drugs.  Furthermore,  as  a  group,  the  anticancer  drugs  are  more  toxic  than  any  other  pharmaceutic  agents,  and  thus  their  benefit  must  be  carefully  weighed  against  their  risks.  Many  of  the  available  drugs  are  cytotoxic  agents  that  act  on  all  dividing  cells,  cancerous  or  normal.  The  ultimate  goal  in  cancer  chemotherapy  is  to  use  advances  in  cell  biology  to  develop  drugs  that  selectively  target  specific  cancer  cells.  A  few  such  agents  are  in  clinical  use,  and  many  more  are  in  development.  
SN  - 
PB  - The McGraw-Hill Companies
CY  - New York, NY
Y2  - 2024/04/20
UR  - accesspharmacy.mhmedical.com/content.aspx?aid=56984734
ER  -